|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Adenine nucleotide-mediated regulation of hepatic PTP1B activity in mouse models of type 2 diabetes.
|
31410531 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
The skeletal muscle activity of protein tyrosine phosphates 1B (PTP1B), a modulator of insulin and IGF-1 signaling, is reduced in obese nondiabetic subjects and in subjects with type 2 diabetes in comparison with leaner, nondiabetic controls.
|
10066387 |
1999 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is a major negative regulator of both the insulin and leptin receptor phosphorylation which impacts insulin sensitivity and hence is a major therapeutic target for the treatment of type 2 diabetes and obesity.
|
31451955 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTP1B is a promising drug target for the treatment of type 2 diabetes, obesity, and cancer.
|
29216799 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our overall results depict <b>1</b>⁻<b>3</b> from <i>M. alba</i> root bark as dual inhibitors of PTP1B and α-glucosidase enzymes, as well as insulin sensitizers.These active constituents in <i>M. alba</i> may potentially be utilized as an effective treatment for T2DM.
|
29786669 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
α-Glucosidases and Protein Tyrosine Phosphatase 1B (PTP1B) are considered important targets for the treatment of T2D: the first digest oligo- and disaccharides in the gut, while the latter regulates the insulin-signaling pathway.
|
30928876 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Since inhibition of PTP1b may prolong the action of the receptor, PTP1b has become a drug target for the treatment of type II diabetes.
|
29347844 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
We and others reported increased abundance of catalytically impaired PTP-1B in tissue lysates from obese human subjects with and without type 2 diabetes, while genetic knockout of PTP-1B improves insulin sensitivity and prevents nutritionally mediated insulin resistance and obesity.
|
11703427 |
2001 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B), a key negative regulator of insulin signaling, is considered as a promising and validated therapeutic target for type 2 diabetes mellitus (T2DM) and obesity.
|
31539748 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
In summary, PTP1B exhibits exquisite substrate specificity and is an outstanding pharmaceutical target for obesity and type 2 diabetes.
|
25263014 |
2015 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B), a negative modulator of insulin and cytokine signaling, is a therapeutic target for type 2 diabetes and obesity.
|
29126873 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is an important therapeutic target for type II diabetes and obesity because of its pivotal role as a negative modulator in both insulin and leptin signalling pathways.
|
28228082 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Developing protein tyrosine phosphatase-1B (PTP1B) inhibitors is an important strategy to treat type 2 diabetes mellitus (T2DM).
|
31585268 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Abbreviations BBB blood-brain barrier CDC25B cell division cycle 25 homolog B CYP2D6 Cytochrome P450 2D6 binding DCCM dynamic cross-correlation map DS Discovery Studio H bond hydrogen bond HIA human intestinal absorption LAR leukocyte antigen-related phosphatase MD molecular dynamics MEG-2 maternal-effect germ-cell defective 2 MM-PBSA molecular mechanics Poisson Boltzmann surface area) PCA principal component analysis PDB Protein Data Bank pNPP p-nitrophenyl phosphate PPB plasma protein binding PTP1B protein tyrosine phosphotase 1B RMSD root mean square deviation RMSF root mean square fluctuation SHP-1 src homologous phosphatase-1 SHP-2 src homologous phosphatase-2 SPC single-point charge TCPTP T cell protein tyrosine phosphatase T2DM Type 2 diabetes mellitus VDW van der Waals Communicated by Ramaswamy H. Sarma.
|
31490104 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is considered a potential target for the treatment of type II diabetes and obesity due to its critical negative role in the insulin signaling pathway.
|
30729132 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) has been identified as a negative regulator of insulin and leptin signalling pathway; hence, it can be considered as a new therapeutic target of intervention for the treatment of type 2 diabetes.
|
28393626 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Insulin resistance caused by the overexpression of protein tyrosine phosphatase 1 B (PTP1B) as well as the dephosphorylation of its target is one of the main causes of type 2 diabetes (T2D).
|
29215104 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTP1B serving as a key negative regulator of insulin signaling is a novel target for type 2 diabetes and obesity.
|
29289892 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
In recent years, PTP1B has become an important target for controlling insulin resistance and type 2 diabetes.
|
30018269 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that variations within the PTPN1 promoter might contribute to the development of T2D and related metabolic traits.
|
17634210 |
2007 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTP1B's direct regulation of the insulin and the leptin receptors makes it an ideal therapeutic target for type II diabetes and obesity.
|
23879520 |
2014 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results suggest that MAFC from J. chinensis has therapeutic potential in T2DM by inhibiting PTP1B and activating insulin signaling pathways.
|
29177868 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) acts as a negative regulator of insulin and leptin signalling and is crucially involved in the development of type 2 diabetes mellitus, obesity, cancer and neurodegenerative diseases.
|
31491569 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Endocellular protein tyrosine phosphatase 1B (PTP1B) is one of the most promising target for designing and developing drugs to cure type-II diabetes and obesity.
|
29048995 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.500 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B), a classical non-transmembrane tyrosine phosphatase, is a pivotal regulator and promising drug target in type 2 diabetes and obesity.
|
26299811 |
2015 |